Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

453
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
453
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.2K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.2K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

634
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
634
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

9.9K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
9.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Glycoprotein IIb/IIIa Blockade: Ready to CELEBRATE a New Dawn?

European cardiology·2026
Same author

Anticoagulants beyond coagulation: a narrative review of cardiovascular effects.

Cardiovascular research·2026
Same author

Apixaban vs vitamin K antagonists in relation to postthrombotic syndrome: data from a prospective cohort study.

Journal of thrombosis and haemostasis : JTH·2025
Same author

Additional oxerutin therapy to promote deep vein thrombus resolution (RESOLVE-DVT): a randomized controlled pilot trial.

Journal of thrombosis and haemostasis : JTH·2025
Same author

Sex differences in outcomes of vitamin K antagonist treatment in patients with a mechanical heart valve: a Dutch population-based cohort study.

Journal of thrombosis and haemostasis : JTH·2025
Same author

Changes in quality of vitamin K antagonist treatment and clinical outcomes during Ramadan: a Dutch population-based cohort study.

Research and practice in thrombosis and haemostasis·2025
Same journal

Prosthetic valve thrombosis: contemporary concepts in diagnosis and management.

Expert review of cardiovascular therapy·2026
Same journal

Life's essential 8 and its role in cardiovascular health: evolution, evidence, and future directions.

Expert review of cardiovascular therapy·2026
Same journal

Efficacy and safety of clopidogrel and aspirin initiated within 72 hours after mild ischemic stroke or high-risk TIA by sex: a prespecified subgroup analysis of the INSPIRES trial.

Expert review of cardiovascular therapy·2026
Same journal

Approaches to transcatheter aortic valve replacement failure: is more focus on prevention required?

Expert review of cardiovascular therapy·2026
Same journal

Vericiguat for heart failure with reduced ejection fraction: a perspective from approval to real-world clinical treatment.

Expert review of cardiovascular therapy·2026
Same journal

Early autonomic neuropathy in prediabetes: an overlooked driver of cardiometabolic risk.

Expert review of cardiovascular therapy·2026
See all related articles

Related Experiment Video

Updated: Mar 15, 2026

RNA-seq Analysis of Transcriptomes in Thrombin-treated and Control Human Pulmonary Microvascular Endothelial Cells
18:30

RNA-seq Analysis of Transcriptomes in Thrombin-treated and Control Human Pulmonary Microvascular Endothelial Cells

Published on: February 13, 2013

22.5K

Upstream versus downstream thrombin inhibition.

Anouk J W Gulpen1,2, Arina J Ten Cate-Hoek1,3, Hugo Ten Cate1,2,3

  • 1a Department of Biochemistry , Maastricht University , Maastricht , The Netherlands.

Expert Review of Cardiovascular Therapy
|August 31, 2016
PubMed
Summary
This summary is machine-generated.

Vitamin K antagonists (VKA) and newer non-vitamin K anticoagulants (NOAC) manage thrombosis but carry bleeding risks. Factor XIa inhibitors represent a promising avenue for safer anticoagulation with fewer bleeding complications.

Keywords:
Anticoagulationfactor XIfactor XIInon-vitamin K antagonist oral anticoagulants (NOACs)vitamin K antagonists (VKA)

More Related Videos

Author Spotlight: Advancing Thrombolytic Testing by Integrating Flow Dynamics in In Vitro Models
06:16

Author Spotlight: Advancing Thrombolytic Testing by Integrating Flow Dynamics in In Vitro Models

Published on: April 19, 2024

2.0K
A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

3.6K

Related Experiment Videos

Last Updated: Mar 15, 2026

RNA-seq Analysis of Transcriptomes in Thrombin-treated and Control Human Pulmonary Microvascular Endothelial Cells
18:30

RNA-seq Analysis of Transcriptomes in Thrombin-treated and Control Human Pulmonary Microvascular Endothelial Cells

Published on: February 13, 2013

22.5K
Author Spotlight: Advancing Thrombolytic Testing by Integrating Flow Dynamics in In Vitro Models
06:16

Author Spotlight: Advancing Thrombolytic Testing by Integrating Flow Dynamics in In Vitro Models

Published on: April 19, 2024

2.0K
A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model
09:42

A Fibrin-Enriched and tPA-Sensitive Photothrombotic Stroke Model

Published on: June 4, 2021

3.6K

Area of Science:

  • Pharmacology
  • Cardiology
  • Hematology

Background:

  • Vitamin K antagonists (VKA) have long been standard for anticoagulation in atrial fibrillation and venous thromboembolism.
  • Non-vitamin K anticoagulants (NOAC) offer comparable efficacy and improved safety, particularly regarding intracranial bleeding.
  • Despite advances, major bleeding events persist, necessitating the development of safer anticoagulant therapies.

Purpose of the Study:

  • To review the current landscape of anticoagulation therapies.
  • To identify unmet needs in the management of non-vitamin K anticoagulants.
  • To explore the potential of novel anticoagulants, such as factor XIa inhibitors, for enhanced safety.

Main Methods:

  • Literature review of VKA and NOAC therapies.
  • Analysis of clinical trial data regarding efficacy and bleeding profiles.
  • Discussion of current challenges in NOAC management and future therapeutic directions.

Main Results:

  • NOACs are effective and safer than VKAs for preventing thrombosis but still associated with major bleeding.
  • Unmet needs in NOAC management include drug selection, dosing, and persistence.
  • Factor XIa inhibitors show potential for improved safety by reducing bleeding complications.

Conclusions:

  • Safer anticoagulation strategies are crucial for managing thrombotic disorders.
  • Factor XIa inhibitors represent a promising 'upstream' approach to anticoagulation.
  • Further research into factor XIa inhibitors may lead to reduced bleeding risks in patients requiring anticoagulation.